A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With P
- This topic has 2 replies, 3 voices, and was last updated 5 years, 1 month ago by
.
-
Posts
-
Hi kgroft,
Thank you for the update. TAS-120 seems a good next step as it has shown in studies to have efficacy in some patients with FGFR mutations who progressed on a different FGFR inhibitor treatment. I hope your husband’s scan goes well and he has the same good long run on this new treatment as he had with the prior FGFR inhibitor trial he participated in.
Take care, regards, Mary
My husband started this trial after having disease progression on Pemigatinib. At his first scan, there was growth, so another scan was scheduled in 1 month. The doctor explained that it may be false progression on the first scan; a second scan will provide more definitive info. The second scan showed continued disease progression and a new, very small met to the lung, so he is no longer on the trial. Tomorrow we’re back to Hopkins for another scan prior to starting expanded use of TAS120.
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
NCT03250273
Gavin
- The forum ‘Clinical Trials’ is closed to new topics and replies.